Cassian Yee
The University of Texas MD Anderson Cancer Center · 367 works · 18,317 citations · h-index 66
Top works
- Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients
- Adoptive T cell therapy using antigen-specific CD8 + T cell clones for the treatment of patients with metastatic melanoma: In vivo persistence, migration, and antitumor effect of transferred T cells
- Tumour-derived soluble MIC ligands impair expression of NKG2D and T-cell activation
- Treatment of Metastatic Melanoma with Autologous CD4+ T Cells against NY-ESO-1
- Isolation of High Avidity Melanoma-Reactive CTL from Heterogeneous Populations Using Peptide-MHC Tetramers
- Melanocyte Destruction after Antigen-Specific Immunotherapy of Melanoma
- Prospects for adoptive T cell therapy
- Autoreactive T Cells in Healthy Individuals
- A possible autocrine role for interleukin-6 in two lymphoma cell lines
- Adoptive immunotherapy: Engineering T cell responses as biologic weapons for tumor mass destruction
- Isolation of tyrosinase-specific CD8+ and CD4+ T cell clones from the peripheral blood of melanoma patients following in vitro stimulation with recombinant vaccinia virus
- CD3- and CD28-Dependent Induction of PDE7 Required for T Cell Activation
- Nephrotoxicity of immune checkpoint inhibitors beyond tubulointerstitial nephritis: single-center experience
- Immune checkpoint inhibitor related myasthenia gravis: single center experience and systematic review of the literature
- Ultra-sensitive detection of rare T cell clones
- IL-21 Influences the Frequency, Phenotype, and Affinity of the Antigen-Specific CD8 T Cell Response
- Generation and testing of clinical-grade exosomes for pancreatic cancer
- Transferred WT1-Reactive CD8 + T Cells Can Mediate Antileukemic Activity and Persist in Post-Transplant Patients
- Modulating T-cell immunity to tumours: new strategies for monitoring T-cell responses
- 1134P Safety and efficacy of low dose (LD) ipilimumab (Ipi) + pembrolizumab (pem) in checkpoint inhibitor (CPI) naïve patients (pts) with melanoma brain metastases (MBM)